StreetAlpha.app
Home › Stocks › VOR

Vor Biopharma Inc. (VOR)

Members
LATEST PRICE

Vor Biopharma is developing telitacicept, an investigational treatment for autoimmune diseases. VOR reports earnings on Wed, Nov 11, 2026.

Prices, price targets and earnings estimates for VOR are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is VOR in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 11
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated VOR in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for VORThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
WedbushMaintained
Aug 12Hold
DateFirmActionRatingPrice target
Aug 12WedbushMaintainedHold
Loading…

Whale Options Flow

90D

No whale options trades in VOR in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VOR is in one of them and how their past VOR trades turned out.

See how it works→ View all auto pilots→
VOR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VOR in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Vor Biopharma

Vor Biopharma is a biopharmaceutical company based in Boston, Massachusetts, that is developing telitacicept, a treatment for autoimmune diseases. Telitacicept is a fusion protein that acts on two signaling molecules involved in B cell activity, and the company is studying it in conditions such as generalized myasthenia gravis and Sjögren's disease. It holds rights to the drug outside Greater China and is running advanced trials aimed at approval in the United States, Europe and Japan. Its intended users are patients with autoimmune diseases and the doctors who treat them.

Headquarters
Boston, MA
Summary based on the company’s 2026 annual report (10-K) ↗